Free Trial

Evolus (EOLS) to Release Earnings on Wednesday

Evolus logo with Medical background

Evolus (NASDAQ:EOLS - Get Free Report) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Evolus to post earnings of ($0.08) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Evolus (NASDAQ:EOLS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Stock Performance

Shares of NASDAQ EOLS traded down $0.37 during mid-day trading on Wednesday, reaching $16.32. 164,021 shares of the company were exchanged, compared to its average volume of 579,724. The company's 50-day simple moving average is $16.19 and its 200-day simple moving average is $13.63. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The stock has a market capitalization of $1.02 billion, a P/E ratio of -15.90 and a beta of 1.31. Evolus has a twelve month low of $7.44 and a twelve month high of $17.82.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.10% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on EOLS shares. Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, September 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research note on Monday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, October 3rd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th.

View Our Latest Stock Report on Evolus

Evolus Company Profile

(Get Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Stories

Earnings History for Evolus (NASDAQ:EOLS)

Should you invest $1,000 in Evolus right now?

Before you consider Evolus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.

While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines